Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 8;12:630773. doi: 10.3389/fimmu.2021.630773

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Lin, Qiu, Zhang and Luo

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Survival curves and genetic characteristics of patients with BLCA stratified by NCOR1 status. (A) Kaplan–Meier estimates of OS in the ICI-treated BLCA cohort comparing patients with NCOR1-MT with their respective counterparts without NCOR1-MT. Patients (BLCA) who harbored NCOR1 mutations showed a better prognosis for ICI-based immunotherapy (P < 0.031, log-rank test). (B) Lollipop plot shows the distribution of NCOR1 mutations in the ICI-treated cohort (top panel) and TCGA-BLCA cohort (bottom panel). GISTIC 2.0 analysis showing the most consistent and relevant cytoband alterations in TCGA-BLCA (C), NCOR1-MT (D) and NCOR1-WT (E). The annotated cytobands met the criterion of false discovery rate (FDR) ≤0.05. ICIs, Immune checkpoint inhibitors; OS, overall survival; BLCA, bladder urothelial carcinoma; NCOR1, nuclear receptor corepressor 1; TCGA, The Cancer Genome Atlas; MT, mutant; WT, wild-type.